PR-1 is a novel nanoparticle formulation of docetaxel (Taxotere), a drug widely used in the treatment of a variety of solid tumor types.The American Cancer Society estimates that 1.6 million new cases of cancer will be reported in the US in 2012, and that 577,000 people will die as a result of this disease. Cancer is the second most common cause of death after heart disease, accounting for nearly one in four deaths. Taxotere generated worldwide revenue of ~$2.7B (€2.1) in 2010. A unique opportunity exists for this novel formulation of docetaxel to capture significant market share based on its improved safety, tolerability and efficacy profile over docetaxel (Taxotere).

PR-2 is a novel formulation of diclofenac prepared by nanoemulsion drug delivery system.Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) indicated for management of mild to moderate acute pain and osteoarthritis (OA) pain.

PR-3 is a novel ciclosporin nanoemulsion eye drops intended for the treatment of severe keratitis in adult patients with dry eye disease (DED).The active substance of PR-3 is ciclosporin, an immunosuppressant belonging to the therapeutic class of ophtalmologicals. Ciclosporin blocks the release of pro-inflammatory cytokines and exerts an anti-inflammatory effect in ocular surface cells.